Stem Cell Research on Cardiology

Even today, cardiovascular diseases are the main cause of death worldwide, and therapeutic approaches are very restricted. Due to the limited regenerative capabilities of terminally differentiated cardiomyocytes post injury, new strategies to treat cardiac patients are urgently needed. Post myocardi...

Full description

Saved in:
Bibliographic Details
Other Authors: David, Robert (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
MEA
PSC
ESC
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_69152
005 20210501
003 oapen
006 m o d
007 cr|mn|---annan
008 20210501s2020 xx |||||o ||| 0|eng d
020 |a books978-3-03943-193-9 
020 |a 9783039431922 
020 |a 9783039431939 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-03943-193-9  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a GP  |2 bicssc 
072 7 |a PS  |2 bicssc 
100 1 |a David, Robert  |4 edt 
700 1 |a David, Robert  |4 oth 
245 1 0 |a Stem Cell Research on Cardiology 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (356 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Even today, cardiovascular diseases are the main cause of death worldwide, and therapeutic approaches are very restricted. Due to the limited regenerative capabilities of terminally differentiated cardiomyocytes post injury, new strategies to treat cardiac patients are urgently needed. Post myocardial injury, resident fibroblasts begin to generate the extracellular matrix, resulting in fibrosis, and finally, cardiac failure. Recently, preclinical investigations and clinical trials raised hope in stem cell-based approaches, to be an effective therapy option for these diseases. So far, several types of stem cells have been identified to be promising candidates to be applied for treatment: cardiac progenitor cells, bone marrow derived stem cells, embryonic and induced pluripotent stem cells, as well as their descendants. Furthermore, the innovative techniques of direct cardiac reprogramming of cells offered promising options for cardiovascular research, in vitro and in vivo. Hereby, the investigation of underlying and associated mechanisms triggering the therapeutic effects of stem cell application is of particular importance to improve approaches for heart patients. This Special Issue of Cells provides the latest update in the rapidly developing field of regenerative medicine in cardiology. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
653 |a Fabry disease 
653 |a human embryonic stem cells 
653 |a CRISPR/Cas9 genomic editing 
653 |a Mass spectrometry proteomic analysis 
653 |a hypertrophic cardiomyopathy 
653 |a disease model 
653 |a physical exercise 
653 |a cardiac cellular regeneration 
653 |a microRNA (miR) 
653 |a Akt signaling 
653 |a cardiomyocyte proliferation 
653 |a cardiac hypertrophy 
653 |a cardioprotection 
653 |a myocarditis 
653 |a inflammation 
653 |a leukocytes 
653 |a cardiomyocytes 
653 |a multi-electrode-array 
653 |a micro-electrode-array 
653 |a MEA 
653 |a drug/toxicity screening 
653 |a field potential 
653 |a arrhythmia 
653 |a electrocardiography 
653 |a cardiac regeneration 
653 |a stem cells 
653 |a iPSC 
653 |a PSC 
653 |a ESC 
653 |a cardiovascular disease 
653 |a regeneration 
653 |a cardiac progenitor cells 
653 |a induced pluripotent stem cells 
653 |a transdifferentiation 
653 |a direct reprogramming 
653 |a genetic engineering 
653 |a cardiac tissue engineering 
653 |a biomaterials 
653 |a 18F-FDG PET 
653 |a cardiac induced cells 
653 |a cardiac function 
653 |a non-invasive imaging 
653 |a human pluripotent stem cell 
653 |a ventricular 
653 |a maturation 
653 |a bone marrow stem cells 
653 |a angiogenesis 
653 |a myocardial infarction 
653 |a human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 
653 |a iPS cells 
653 |a big conductance calcium activated potassium channel (BK) 
653 |a Maxi-K 
653 |a slo1 
653 |a KCa1.1 
653 |a iberiotoxin 
653 |a long QT syndrome 
653 |a mesenchymal stromal cells (MSC) 
653 |a mRNA 
653 |a miRNA 
653 |a cardiac reprogramming 
653 |a cardiac differentiation 
653 |a cardiovascular diseases 
653 |a adult stem cells 
653 |a myocardial infraction 
653 |a 3D printing 
653 |a 3D model 
653 |a bioprinting 
653 |a cardiovascular medicine 
653 |a heart 
653 |a myocardium 
653 |a heart valves 
653 |a vascular graft 
653 |a endothelialization 
653 |a tissue engineering 
653 |a decorin 
653 |a fibronectin 
653 |a electrospinning 
653 |a endothelial progenitor cells 
653 |a bioreactor 
653 |a biostable polyurethane 
653 |a MicroRNA 
653 |a Mir-133 
653 |a coronary heart disease 
653 |a biomarker 
653 |a meta-analysis 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/2924  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/69152  |7 0  |z DOAB: description of the publication